Despite perfect match, doctors say little Hannah Day is too weak for transplant

;

Hannah Day needs a life saving stem-cell transplant. Her family is not a match.

A sad update to the story of four-year-old Hannah Day.

Hannah lives in Victoria and has been in and out of hospital for most of her short life. She has leukemia andandits the second timein as many years that she is battling cancer.

The Day family went public just after Christmas to try and find a stem-cell donor for Hannah. Thousands of people from around the province rallied behind the Day family who finally got their wish, a perfect match.

But doctors say the little girl has gone through too much radiation to successfully have a stem-cell transplant, leaving her family with the choice of palliative care or a risky transplant next month that has a 60 per cent chance of success.

Canada currently has 326,000 people who are already registered as potential stem-cell donors. Hannah is one of 750 Canadians who are currently awaiting a stem-cell transplant.

To become a stem-cell donoryou can fill out a questionnaire onlineif youre between the ages of 17 and 35, and youll be sent a kit in the mail. A swab of your cheeks will reveal if youre a suitable donor. Once identified as a match, donors will undergo one of two procedures. Stem cells can be harvested from bone marrow under general anesthetic, or throughperipheral blood stem cell donation.

Shaw Media, 2014

Amy started with Global BC in June 2011, and loves being part of such an exciting newsroom. She loves social media and is always looking for a good story! You can also catch her on Trending on and BC1.

See the rest here:
Despite perfect match, doctors say little Hannah Day is too weak for transplant

New protein breakthrough brings leukemia cure closer to reality

Washington, Feb 03 : A team of researchers has identified a protein critical to hematopoietic stem cell function and blood formation.

The finding has potential as a new target for treating leukemia because cancer stem cells rely upon the same protein to regulate and sustain their growth.

Principal investigator Tannishtha Reya from the University of California, San Diego School of Medicine, along with her colleagues found that a protein called Lis1 fundamentally regulates asymmetric division of hematopoietic stem cells, assuring that the stem cells correctly differentiate to provide an adequate, sustained supply of new blood cells.

Asymmetric division occurs when a stem cell divides into two daughter cells of unequal inheritance: One daughter differentiates into a permanently specialized cell type while the other remains undifferentiated and capable of further divisions.

"This process is very important for the proper generation of all the cells needed for the development and function of many normal tissues," Reya said. When cells divide, Lis1 controls orientation of the mitotic spindle, an apparatus of subcellular fibers that segregates chromosomes during cell division.

When researchers deleted Lis1 from mouse hematopoietic stem cells, differentiation was radically altered. Asymmetric division increased and accelerated differentiation, resulting in an oversupply of specialized cells and an ever-diminishing reserve of undifferentiated stem cells, which eventually resulted in a bloodless mouse.

Reya said that they found that a large part of the defect in blood formation was due to a failure of stem cells to expand. Instead of undergoing symmetric divisions to generate two stem cell daughters, they predominantly underwent asymmetric division to generate more specialized cells.

As a result, the mice were unable to generate enough stem cells to sustain blood cell production, the researcher said.

Reya said the findings shed new light on the fundamental regulators of cell growth both in normal development and in cancer.

The study was published in the journal Nature Genetics.

More here:
New protein breakthrough brings leukemia cure closer to reality

Progress in stem cell biology: This could change everything about the practice of medicine

Editors note: What follows is a guest post. Michael Zhang is an MD-PhD student studying at the University of Louisville School of Medicine. He is one of my go-to experts on matters of cell biology and stem cells. (His bio is below.)

As you may have heard, this week brought striking news in the field of stem cell biology. Researchers from Boston and Japan published two papers in the prestigious journal Nature in which they describe new and easy ways to transform mouse cells back into stem cells. (NPR coverage here.) Make no mistake, this is not mundane science news. This is big.

I follow cell biology because I believe it is the branch of science that will bring the next major advance in modern medicine. Rather than implant a pacemaker, future doctors may inject a solution of sinus node stem cells, and voila, the heart beats normally. Rather than watch a patient with a scarred heart die of heart failure or suffer from medication side effects, future doctors may inject stem cells that replace the non-contracting scar. And the same could happen for kidneys, pancreas, spinal nerves, etc.

When I heard the news, I emailed Michael the link with the following subject line: This is pretty cool, right? He wrote back. What he taught me is worth sharing.

***

Michael Zhang MD-PhD candidate Univ of Louisville

By Michael Zhang:

Japanese and American cell biologists have recently reported dramatic new findings that are likely to upend biological dogma.

For much of the past century, the prevailing consensus held that once animal cells move past the earliest embryonic stages, they are irreversibly committed to specialized roles in the adult brain cells, heart cells, lung cells etc. In the past decade, two Nobel-winning biologists each separately demonstrated that committed specialist cells (aka differentiated cells) could be reprogrammed back to a primordial, embryonic state (aka pluripotent stem cell) that could then morph into any new type of specialized cell.

Now, Professor Obokata and her colleagues describe new methods to induce this reprogramming of specialized cells to (pluripotent) stem cells. Whereas previous methods involved draconian procedures the transfer of entire nuclei between cells, or the transfer of multiple genes Obokatas group found that simply squeezing a terminally differentiated cell, or immersing it in an acidic solution, could induce reprogramming to an embryonic stem cell state.

Excerpt from:
Progress in stem cell biology: This could change everything about the practice of medicine

stem cell therapy treatment for traumatic brain injury by dr alok sharma, mumbai, india – Video


stem cell therapy treatment for traumatic brain injury by dr alok sharma, mumbai, india
improvement seen in just 5 days after stem cell therapy treatment for traumatic brain injury by dr alok sharma, mumbai, india. Stem Cell Therapy done date 7 ...

By: Neurogen Brain and Spine Institute

Originally posted here:
stem cell therapy treatment for traumatic brain injury by dr alok sharma, mumbai, india - Video

TiGenix : reaches major cell therapy milestone with 1000th.

REGULATED INFORMATION FEBRUARY 4, 2014

TiGenix reaches major cell therapy milestone with 1000th implant of ChondroCelect

Leuven (BELGIUM) - February 4, 2014 - TiGenix (NYSE Euronext: TIG), a leader in the field of cell therapy, announced today that it reached a major milestone with the performance of the 1000th ChondroCelect implantation for cartilage repair in the knee. ChondroCelect is the first cell therapy that was granted approval by the European Medicines Agency (EMA) as an Advanced Therapy Medicinal Product (ATMP). Today it is routinely used in orthopedic centers of excellence across several European countries.

"A 1000 patients have already benefited from this innovative therapy, further supporting its efficacy and safety profile," said Eduardo Bravo, CEO of TiGenix. "A milestone such as today's is a clear demonstration of how far the cell therapy field has progressed over recent years, and I have no doubt that it is on its way to become a mainstay in clinical practice. We will continue to work towards turning our ChondroCelect franchise into a cash flow positive asset, and to push the clinical development of our pipeline of stem cell programs to a successful conclusion."

About ChondroCelect An innovative treatment, ChondroCelect has been shown to result in long-term durable clinical benefits in patients with recent cartilage lesions. Five-year follow-up data confirm that the therapeutic effect and the clinical benefit of ChondroCelect gained over baseline is maintained up to at least five years after the cartilage repair intervention. In addition, the data confirm that early treatment with ChondroCelect results in a superior clinical benefit over microfracture, and a lower failure rate.

Cartilage lesions of the knee are a frequent cause of disability in the active population. Caused by repetitive microtraumata, or due to sports or traffic accidents, cartilage lesions rarely heal spontaneously. When untreated, they predispose to osteoarthritis, which causes disability and represents a major socioeconomic burden. A treatment that allows symptom relief and functional recovery is key. To meet this important medical need, TiGenix developed ChondroCelect, the first cell therapy that was granted approval by the EMA as an ATMP.

ChondroCelect is administered to patients in an autologous chondrocyte implantation procedure known as Characterized Chondrocyte Implantation. TiGenix has designed a sophisticated manufacturing process to preserve the cells' characteristics and biological activity, and to maintain their ability to produce high quality cartilage. This process meets the highest quality standards and has been approved by the EMA.

For more information: Eduardo Bravo Chief Executive Officer eduardo.bravo@tigenix.com

Claudia D'Augusta Chief Financial Officer claudia.daugusta@tigenix.com

About TiGenix

Read the original here:
TiGenix : reaches major cell therapy milestone with 1000th.

Stem cell treatment: Controversial for humans, but not for pets

PHOENIX, Ariz. -

Stem cell research and therapy on humans has traveled a long and often politically troubled path.

Not so for pets, where stem cell treatment has been used for nearly 10 years and now it is so routine, and so successful, it can be done in a day.

Ava is a 90 pound, 2-year-old Akita, who is about to undergo stem cell surgery. A little IV, a little anesthesia and Ava is out.

"It is used for arthritis mostly," said Dr. Velvet Edwards.

Ava is just beginning her day at Pecan Grove Veterinary Hospital in Tempe. Dr. Edwards oversees the stem cell procedure.

"Stem cells are healing cells, so they seek out area of injury damage or destruction," explained Edwards. "They accelerate healing and help the animal, the patient, the pet just use their own natural abilities to get better."

Veterinary stem cells are harvested from the animal's own fat cells. They are separated and processed by machinery right inside the vet's office and then injected back into the dog's trouble spots.

Thanks to new technology developed by Meti Vet, the process is completed in just a day.

"The pet comes in the morning, it's anesthetized and I collect about two to four grams of fat usually behind the shoulder blade," said Edwards. "Then I hand that fat over to my technicians to run it through a series of steps.. basically to dissolve the fat and get down to a little stem cell pellet... Then we take that pellet and we reconstitute it and make it injectable. I will put it back into the animal's body wherever I need it later that day."

More here:
Stem cell treatment: Controversial for humans, but not for pets

Center for Stem Cell & Regenerative Medicine – UTHealth

Phone 713.500.3429; Fax 713.500.2424

Brian R. Davis, Ph.D., Associate Professor and DirectorQi Lin Cao, M.D., Associate Professor Charles S. Cox, Jr., M.D., Professor Radbod Darabi, M.D., Ph.D., Assistant ProfessorDong H. Kim, M.D., ProfessorMikhail G. Kolonin, Ph.D., Associate Professor Yong Li, M.D., Ph.D., Associate Professor Ying Liu, M.D., Ph.D., Assistant Professor Nami McCarty, Ph.D., Assistant Professor Naoki Nakayama,Ph.D., Associate Professor Laura A. Smith Callahan,Ph.D., Assistant Professor Pamela L. Wenzel, Ph.D. Assistant Professor Jiaqian Wu, Ph.D., Assistant Professor

About the Center

A major focus of contemporary medicine is the development of effective therapies for the restoration of human tissues and organs lost to diseases and trauma. Regenerative Medicine is a rapidly emerging field that stands at the intersection of a variety of rapidly developing scientific disciplines: stem cell biology, tissue engineering, biomaterials, molecular biology, immunology and transplantation biology and clinical research. Implicit in the successful design, implementation and application of regenerative medicine/tissue engineering approaches to the repair of a damaged tissue or organ is the reliance on the unique biological properties of stem cells.

The mission statement of the Center for Stem Cell and Regenerative Medicine at the IMM is: To study the fundamental properties of stem cells and to translate their unique biological properties into novel cellular therapies for graft engineering and tissue regeneration for currently intractable disorders. While it is therefore implicit that any such program would span basic-translational-clinical research, it is essential that such an endeavour is ultimately underpinned by excellence in fundamental stem cell research. The Director of the Center, Dr. Brian R. Davis is currently in the process of recruiting a multidisciplinary faculty with the appropriate breadth of expertise, innovation and scientific rigour in the discipline of stem cell biology with the dual intention to promote the excellence and innovation of research within the Center and secondly to ensure the quality and appropriateness of stem cell based translational research initiatives emanating from the Center. In addition, the Center is also envisioned as an educational resource, which in the medium to long-term will be the basis for the development of an academic program in stem cell biology on campus. Moreover, by interfacing effectively with other programs and institutions within the UTHSC, the Center will also act as a focus to stimulate the development and implementation of novel cellular therapies for a range of diseases and disorders.

Some of the current areas of research in the Center are highlighted below:

Brian R. Davis, Ph.D. Associate Professor of Molecular Medicine & Director, Center for Stem Cell and Regenerative Medicine Annie and Bob Graham Distinguished Chair in Stem Cell Biology Ph.D. ~ California Institute of Technology / Pasadena, California

Qi Lin Cao,M.D. Associate Professor, The Vivian L. Smith Department of Neurosurgery & Center for Stem Cell and Regenerative Medicine M.D.~ Hunan Medical University / Hunan, China

Continued here:
Center for Stem Cell & Regenerative Medicine - UTHealth

Stem Cell Medical Research Center

Functions of organism last properly depending on well organized and controlled reproduction, immigration, differentiation and maturation activities unions. It is possible when the cells in organ and tissues are produced regularly. Stem cells are at the top of this system in an organism. Stem cell is that are able to renew themselves by keeping on splitting for long time by remaining same (not differentiated) and they can differentiate according to needs of organism. Stem cells are major source of cell based treatments. Thus some of researches are using human or animal based stem cells from different kind of tissues.

In different kinds of stem cell researches state that mature stem cell have some significant advantage on the cure of damaged tissues. The advantage of using stem cell obtained from an adult is that stem cell can reproduce in patients own cultivation and then before facing regeneration, they can be given to the patient.

Stem cell researches and its treatments are still the very popular topic in the world

STEM CELLS AND WHY ARE THEY IMPORTANT?

Research of stem cell has gained much prominence in recent years for its therapeutic potential in dealing with diseases many of which are essentially incurable by normal therapies. These diseases are characterized by progressive cell loss which has no regenerative potential: e.g. neurodegenerative process leads to Alzheimer and Parkinson diseases. These have become serious health problems as people in advanced societies now live longer. There is great variability in the occurrence and onset of these diseases and the underlying environmental and genetic factors are unknown. The destruction of the beta cells of pancreatic islets is the main cause of diabetes, another serious health problem, can be caused by autoimmune reactions resulting in cell loss (1).

Stem cells are distinct from other cell types by two important characteristics. First, they are unspecialized cells capable of renewing themselves through cell division, sometimes after long periods of inactivity (in G0). Second, under certain physiologic or experimental setting, they can be induced to become tissue or organ specific cells with special functions (2). In some organs, stem cells regularly divide to repair and replace worn out or damaged tissues such as the gut and bone marrow. In other organs, however, such as the heart and the pancreas, stem cells only divide under special conditions. They have the remarkable potential to develop into many different cell types in the body during early life and growth. On the other hand, they serve as a sort of internal repair system in many tissues, dividing essentially without limit to replenish other cells as long as the person or animal is still alive (2).

Scientists frequently worked with two kinds of stem cells from animals and humans: embryonic stem cells and non-embryonic somatic or adult stem cells. Researchers discovered ways to derive embryonic stem cells from early mouse embryos nearly 30 years ago, in 1981. In 1998, the detailed study of the biology of mouse stem cells led to the discovery of a method to derive stem cells from human embryos and grow the cells in the laboratory. These cells are called human embryonic stem cells. They are important for living organisms for many reasons. In the 3- to 5-day-old embryo, called a blastocyst, the inner cells give rise to the entire body of the organism, including all of the many specialized cell types and organs such as the heart, lung, skin, sperm, eggs and other tissues. In some adult tissues, such as bone marrow, muscle, and brain, discrete populations of adult stem cells generate replacements for cells that are lost through normal wear and tear, injury, or disease (2,3).

In 2006, researchers made another breakthrough by identifying conditions that would allow some specialized adult cells to be reprogrammed genetically to assume a stem cell-like state. This new type of stem cell was called induced pluripotent stem cells (iPSCs) (2).

Go here to read the rest:
Stem Cell Medical Research Center

Stem Cell Clinic

With Focus on Adult Stem Cells to Treat Chronic Degenerative Diseases The Stem Cell Clinic is a multi-institutional center, dedicated to ensuring an uncompromising level of quality care.

Dr. Francisco Contreras, an extensively trained oncologist and surgeon, leads the Stem Cell Clinic in its effort to providing safe and effective regenerative therapies including the use of adult stem cell treatments, nutrition and immune building protocols.

Learn More...

The Stem Cell Clinic advocates and practices the use of adult stem cells, as there are no ethical or moral issues related to their use as compared to embryonic stem cells. There are also more successful treatments confirmed with the use of adult stem cells over embryonic.

Dr. Francisco Contreras demonstrates the procedure to harvest stem cells from the bone marrow.

Watch the Video

If you are searching for experienced surgeons that can provide the treatment and care you deserve, contact the Stem Cell Clinic today. Our clinic provides the highest quality of support to patients from around the world. If you would like to schedule a consultation, please fill out our request form, and a member of our staff will contact you shortly.

See the original post:
Stem Cell Clinic

More Stem Cell Clinic Hype Press Releases for the New Year …

This week I saw yet another crazy press release. I usually see these from some university claiming a stem cell first that isnt close to a first. Yet now they also seem to be coming from doctors who are claiming firsts that are no where near firsts. This one was from an Orthopedic Sports doctor who claims to be the only orthopedic surgeon in the country using stem cells (we have a few in our network and bone marrow stem cells have been in common use by surgeons for at least a decade). The story was so riddled with inaccuracies (stem cells coming from blood, stem cells not being common practice because of the Bush Embryonic stem cell ban, that there is something unique about a little bedside centrifuge processing bone marrow), that I thought it was time to again differentiate what we do from the wild west of stem cell clinics cropping up.

When we first pioneered orthopedic stem cell therapy in 2005, we were the only physicians in the U.S. doing this type of work. This last few years has seen a bevy of clinics opening up and offering stem cell therapies for pretty much whatever ails you-from arthritis to ALS to COPD to MS. A few of these clinics are legitimately trying to do a good job, but most are not. How can you tell the difference? First, lets look at the clinic types that are popping up:

The Miracle Fat Stem Cell Clinic-These clinics offer treatments for a multitude of diseases that include knee and hip arthritis. They perform a small liposuction to get cells and as such, are usually run by a plastic surgeon who oversees a processing facility that distributes cells to other medical specialists. Some claim to be operating research studies, but when I have investigated these further, most of this is more sales than reality (i.e. one clinic system claimed to have a research IRB approval that turned out to have been rescinded). In addition, on the orthopedics side of the treatments, these are usually blind non-specific injections (without any guidance to ensure accurate placement) somewhere in the vicinity of the painful joint. They frequently will combine these local injections with an IV infusion of fat stem cells, 97% of which will end up in the lungs and never see the joint. As you know from previous blogs, fat stem cells dont work as well as marrow cells for orthopedic purposes, so the orthopedic side of the business seems to be an afterthought to drive revenue.

The Little Bedside Machine Clinic-These clinics are often more focused on orthopedic problems, but use an automated bedside one size fits all machine to process bone marrow cells and platelet rich plasma. Some of these clinics do offer guidance of the injection, but very little effort is placed on tracking patients or reporting outcome data. So the type of treatment registry data that youve read about on this site over the past month isnt going to be reported by these clinics, leaving the patient to fly blind on how well these procedures work or dont work. These machines also produce about 1/10-1/15th of the stem cells per unit volume as a Regenexx-SD procedure (based on our lab studies). They also only isolate one fraction in the bone marrow that contains stem cells and discard the other fraction (not knowing that it has valuable cells).

So what key components should a clinic have so you can feel comfortable?

Treatment Registry Tracking of Patients

Any new therapy that is yet standard of care needs to have data collected, even if it looks very promising from the standpoint of patient experience (i.e. a doctor says it has worked well in other patients). This means that standardized questionnaires are sent to the patient at set time points to see if they have less pain, more function, or had any complications with the procedure. This is a huge commitment on the part of the clinic and the doctor. As an example, right now we have a Clinical Research organization quality customized software to assist us in collecting data on the patients weve treated. We have two full-time employees to collect data, several part time supervisors, and a full time bio statistician to analyze this data. When we want to report the data, we must enlist the help of expensive physicians to call patients who havent responded to their questionnaires as this helps to make sure we have enough data to report. While we have a bio statistician, we must then use more expensive doctor time to help him decide whats clinically meaningful to analyze.

How can you tell if a clinic is doing this? They will have data from their patients that they have collected and reported, usually on an annual basis. As an example, the clinic mentioned above with the little bedside centrifuge that claimed magic, had no data and just began doing this procedure, so you wouldnt expect there to be any. Why is it important to see that clinics data? A procedure like this may produce very different results in a different doctors hands. In addition, the clinic will be able to tell you exactly how it collects its data, who collects it, how often, etc For example, a proper treatment registry collects data at set time points like 1 month, 3 months, 6 months, 1 year, 2 years, 3 years, etc If all you get is a call from a nurse like you would after any common surgery, then this isnt nearly enough.

Guidance of the Injection

Continue reading here:
More Stem Cell Clinic Hype Press Releases for the New Year ...